---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-018894"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:52:46.488239+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech swings to Q2 profit of $0.21/sh; NERLYNX revenue up 5%

## Summary
- GAAP net income $9.4M ($0.21 per share) vs net loss of $5.1M ($0.13 loss) in Q2 2021.
- Total revenue $59.5M ($51.3M product, $8.2M royalties) vs $53.4M in Q2 2021.
- Operating expenses fell sharply: SG&A $20.6M (down 48%), R&D $11.9M (down 36%).
- Cash and securities $60.8M at June 30, down from $82.1M at Dec 31, 2021.
- Management guides for FDA meetings on registration pathways for neratinib in H2 2022.

## SEC filing metadata
- accession: 0001437749-22-018894
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774922018894/0001437749-22-018894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774922018894/pbyi20220802_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-018894
- JSON: https://secwatch.observer/filing/0001437749-22-018894.json
- Plain text: https://secwatch.observer/filing/0001437749-22-018894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.